

**For Immediate Release**

**MedX Health Corporation Announces Discussions  
For the North American Marketing Rights to  
Cardiology Telemedicine Technology**

*Discussions Underway with Medical Marketing Berlin for Rights  
To the H'andy sana 211 cell phone with integrated ECG capability*

**Mississauga, ON – July 26, 2010 – MedX Health Corp., (TSXV.MDX)** a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, announced today that MedX Health Corp. entered into discussions with Medical Marketing Berlin GmbH (MMB) for the exclusive marketing rights to the H'andy sana 211, a touch screen cell phone with an integrated ECG and a "Health Suite" in which blood glucose, cholesterol and blood pressure, etc. can be managed.

Medical Marketing Berlin (MMB) is focused on serving the sales and marketing needs of North American health care companies and is the European master distributor for MedX laser and light products. MMB had previously obtained the worldwide rights to this telemedicine technology. The device allows cardiac patients to measure an ECG in a critical situation remotely, and to send it via SMS to a telemedicine centre, hospital, or private physician to receive an immediate evaluation.

"MedX has an ongoing research and development project in telemedicine in the area of wound care, with our Photobandage™ and WoundSmart™ product innovations, and the H'andy sana 211 would allow us to expand upon our vision in developing products that monitor patients remotely and transmit critical, sometimes life saving information, in a rapid fashion," stated Steve Guillen, president and CEO of MedX Health Corp.

A final agreement will be subject to TSX Exchange, Board, and shareholder approvals, as well as any required third-party consents, satisfactory due diligence, and the signing of a definitive agreement.

**About MedX Health Corp.**

MedX is a leading North American developer and manufacturer of low level laser and light medical devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical settings including dental, rehabilitation and wound care. MedX is the world's only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for, the bringing of non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX's strategy is to build upon its success in bringing relief of conditions in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as

well as developing and commercializing advanced products in the dental and wound-care markets that will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its “*Photobandage*™”, a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

Brand products are US FDA approved, Health Canada cleared, and CE Marked and are produced in an ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX Health Corp. and its products visit [www.medXhealth.com](http://www.medXhealth.com)

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

**Contacts:**

Investors:

Steve Guillen  
President and Chief Executive Officer  
MedX Health Corp.  
Phone: (905) 826-0766  
[info@medxhealth.com](mailto:info@medxhealth.com)

*The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.*